全文获取类型
收费全文 | 13423篇 |
免费 | 1412篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 135篇 |
儿科学 | 291篇 |
妇产科学 | 312篇 |
基础医学 | 1966篇 |
口腔科学 | 218篇 |
临床医学 | 1555篇 |
内科学 | 2696篇 |
皮肤病学 | 149篇 |
神经病学 | 1269篇 |
特种医学 | 520篇 |
外国民族医学 | 10篇 |
外科学 | 1848篇 |
综合类 | 327篇 |
一般理论 | 7篇 |
预防医学 | 1256篇 |
眼科学 | 287篇 |
药学 | 1018篇 |
中国医学 | 18篇 |
肿瘤学 | 987篇 |
出版年
2022年 | 119篇 |
2021年 | 285篇 |
2020年 | 169篇 |
2019年 | 275篇 |
2018年 | 317篇 |
2017年 | 233篇 |
2016年 | 234篇 |
2015年 | 291篇 |
2014年 | 364篇 |
2013年 | 506篇 |
2012年 | 755篇 |
2011年 | 814篇 |
2010年 | 421篇 |
2009年 | 397篇 |
2008年 | 673篇 |
2007年 | 652篇 |
2006年 | 657篇 |
2005年 | 658篇 |
2004年 | 602篇 |
2003年 | 556篇 |
2002年 | 553篇 |
2001年 | 362篇 |
2000年 | 352篇 |
1999年 | 290篇 |
1998年 | 153篇 |
1997年 | 111篇 |
1996年 | 123篇 |
1995年 | 119篇 |
1994年 | 95篇 |
1993年 | 78篇 |
1992年 | 241篇 |
1991年 | 208篇 |
1990年 | 187篇 |
1989年 | 187篇 |
1988年 | 181篇 |
1987年 | 177篇 |
1986年 | 193篇 |
1985年 | 186篇 |
1984年 | 117篇 |
1983年 | 125篇 |
1982年 | 84篇 |
1979年 | 134篇 |
1978年 | 108篇 |
1977年 | 81篇 |
1976年 | 100篇 |
1975年 | 76篇 |
1974年 | 108篇 |
1973年 | 131篇 |
1972年 | 98篇 |
1970年 | 75篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
5.
6.
Facundo Davaro Jacob Roberts Allison May Coleman McFerrin Sameer Siddiqui Zachary Hamilton 《Journal of robotic surgery》2020,14(3):447-454
Partial nephrectomy is the mainstay of treatment for localized kidney cancer. A proportion of patients are upstaged post-operatively to locally advanced di 相似文献
7.
8.
Calcified tissue is a common component of atherosclerotic plaques, and occurs most often in mature plaques. The process of calcification is a poorly understood risk factor that may contribute to a plaque's vulnerability to sudden rupture. In this study a solid-state imaging sequence, termed single-point imaging (SPI), was used to observe calcification directly in ex vivo atherosclerotic plaques. Standards were used to validate the ability of (31)P SPI to detect and differentiate calcification from crystalline cholesterol, phospholipids, and other plaque components. After suitable experimental parameters were found, human carotid specimens obtained by endarterectomy were imaged ex vivo by (31)P solid-state imaging and standard (1)H methods. In contrast to (1)H imaging methods, (31)P imaging detected only the calcification in the plaque. 相似文献
9.
Shannon M. Rush DPM FACFAS Lawrence A. Ford DPM FACFAS Graham A. Hamilton DPM FACFAS 《The Journal of foot and ankle surgery》2006,45(3):156-160
To evaluate morbidity associated with surgical lengthening of the gastrocnemius, medical records were reviewed retrospectively for 126 patients (mean age, 49.7 years; range, 8-78 years) who had undergone open gastrocnemius recession. Ten patients had isolated recession; 116 had gastrocnemius recession with an additional foot or ankle procedure on the ipsilateral limb. During a mean follow-up period of 19 months (range, 6-50 months), all patients were examined for any postoperative complications associated with the recession. Complications were defined as the presence of postoperative infection, wound dehiscence, nerve problems, decreased muscle strength, scar problems, or calcaneus gait (overlengthening). Uncomplicated outcome was defined as absence of all these complications and return to regular activity, both occurring during a follow-up of at least 6 months. Postsurgical complications developed in 9 (6%) of the 126 patients: 6 (4%) had scar problems, 2 (1.33%) had wound dehiscence, 2 (1.33%) had infection, 3 (2%) had nerve problems, and 1 (0.67%) developed complex regional pain syndrome. No patient complained of either a limp or gait disturbance. Neither persistent decrease in muscle strength nor calcaneus gait was seen. These data suggest that the open gastrocnemius recession procedure has low associated morbidity. 相似文献
10.
BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. 总被引:2,自引:0,他引:2
A Hamilton L Elrick S Myssina M Copland H J?rgensen J V Melo T Holyoake 《Leukemia》2006,20(6):1035-1039
In chronic myeloid leukaemia, CD34(+) stem/progenitor cells appear resistant to imatinib mesylate (IM) in vitro and in vivo. To investigate the underlying mechanism(s) of IM resistance, it is essential to quantify Bcr-Abl kinase status at the stem cell level. We developed a flow cytometry method to measure CrkL phosphorylation (P-CrkL) in samples with <10(4) cells. The method was first validated in wild-type (K562) and mutant (BAF3) BCR-ABL(+) as well as BCR-ABL(-) (HL60) cell lines. In response to increasing IM concentration, there was a linear reduction in P-CrkL, which was Bcr-Abl specific and correlated with known resistance. The results were comparable to those from Western blotting. The method also proved to be reproducible with small samples of normal and Ph(+) CD34(+) cells and was able to discriminate between Ph(-), sensitive and resistant Ph(+) cells. This assay should now enable investigators to unravel the mechanism(s) of IM resistance in stem cells. 相似文献